Results 41 to 50 of about 22,759 (276)

When Two are Better than One: Modeling the Mechanisms of Antibody Mixtures [PDF]

, 2019
It is difficult to predict how antibodies will behave when mixed together, even after each has been independently characterized. Here, we present a statistical mechanical model for the activity of antibody mixtures that accounts for whether pairs of antibodies bind to distinct or overlapping epitopes.
arxiv   +1 more source

AntiBARTy Diffusion for Property Guided Antibody Design [PDF]

arXiv, 2023
Over the past decade, antibodies have steadily grown in therapeutic importance thanks to their high specificity and low risk of adverse effects compared to other drug modalities. While traditional antibody discovery is primarily wet lab driven, the rapid improvement of ML-based generative modeling has made in-silico approaches an increasingly viable ...
arxiv  

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody‐Dependent Cytotoxicity

Angewandte Chemie, EarlyView.
This study presents novel macrocyclic peptides with low nanomolar affinity for CD59, an immunomodulatory cell surface receptor associated with human disease. Crystallographic and structure‐activity relationship (SAR) studies reveal peptide CP‐06 mimics the binding of biologically relevant CD59 interaction partners. Dimeric and lipidated CP‐06 analogues
Jasmine K. Bickel, Ammar. I. S. Ahmed, Aidan B. Pidd, Rhodri M. Morgan, Tom E. McAllister, Sam Horrell, Emma C. Couves, Hemavathi Nagaraj, Edward J. Bartlett, Kamel El Omari, Akane Kawamura, Doryen Bubeck, Edward W. Tate   +12 more
wiley   +2 more sources

Bispecific antibody (ABL602 2 + 1) induced bistable acute myeloid leukemia kinetics

Scientific Reports
ABL602 2 + 1, a bispecific antibody with two distinct domains binding to CLL-1 on leukemias and CD3 on T cells, exhibits superior T cell activation and tumour lysing activity.
Shilian Xu
doaj   +1 more source

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells

Frontiers in Oncology, 2019
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases ...
Sakthi Rajendran, Sakthi Rajendran, Yating Li, Yating Li, Evelyn Ngoh, Hiu Yi Wong, Hiu Yi Wong, Man Si Cheng, Man Si Cheng, Cheng-I Wang, Herbert Schwarz, Herbert Schwarz   +11 more
doaj   +1 more source

xTrimoABFold: De novo Antibody Structure Prediction without MSA [PDF]

arXiv, 2022
In the field of antibody engineering, an essential task is to design a novel antibody whose paratopes bind to a specific antigen with correct epitopes. Understanding antibody structure and its paratope can facilitate a mechanistic understanding of its function.
arxiv  

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy [PDF]

, 2016
Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them.
Basilico, Cristina, Blanchetot, Christophe, de Haard, Hans, De Jonge, Natalie, El Khattabi, Mohamed, Godar, Marie, Hanssens, Valérie, Hultberg, Anna, Lambrecht, Bart, Michieli, Paolo, Morello, Virginia, Sadi, Ava, Saunders, Michael   +12 more
core   +2 more sources

Nanoparticle‐Mediated Targeted Protein Degradation: An Emerging Therapeutics Technology

Angewandte Chemie, EarlyView.
Targeted protein degradation (TPD) has emerged as a powerful therapeutic approach, with numerous candidates molecules now advancing into clinical development. Recent innovations have incorporated nanoparticles to facilitate and enhance these degradation processes, yielding synergistic effects.
Andrew G. Baker, Adrian Pui Ting Ho, Laura S. Itzhaki, Ljiljana Fruk   +3 more
wiley   +2 more sources